Dublin, Dec. 23, 2016 -- Research and Markets has announced the addition of the "Global Pharmaceutical Contract Manufacturing Market 2016-2020" report to their offering.
The global pharmaceutical contract manufacturing market to grow at a CAGR of 6.91% during the period 2016-2020.
The report covers the present scenario and the growth prospects of the global pharmaceutical contract manufacturing market for 2016-2020. To calculate the market size, the report considers the revenue generated from various pharmaceutical drug manufacturing outsourcing activities. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
One of latest trends in the market is consolidation through vertical integration, alliances, and acquisitions. The major pharmaceutical companies have decreased their operations and R&D budgets, which has led to an increase in demand for outsourced services. Moreover, companies have consolidated their infrastructure in response to a sharp global economic downturn, poor revenue growth prospects, and expensive and inefficient operations.
Strategic partnerships between pharmaceutical companies and CMOs have led to the reduction of government spending on manufacturing. The past few years have brought major changes to the pharmaceutical outsourcing services. As more in-house positions have been removed, pharmaceutical vendors are looking for strategic partnerships and 'one-stop' solutions.
Further, the report states that one major challenge in the market is lack of information integration. One of the greatest challenges faced by most vendors in the pharmaceutical contract manufacturing market is the lack of transparency and information integration in the whole supply chain process. Few medicines, especially vaccines and specialty injections, need fast delivery to ensure their utility. If companies are equipped with a centralized system, they will be able to observe changes in inventory and can order shipments as per requirements. Distribution vehicles or shipments can be redirected to obtain drugs in the required areas.
With the right integration of available data from all the stages within the supply chain, companies can keep track of orders and delivery rates. This can effectively cure the delays and disruptions in the pharmaceutical supply chain, making the entire value chain effectively responsive to the unmet medical needs.
Key vendors
- Catalent
- Lonza
- Pfizer CentreOne
Key Topics Covered:
Part 01: Executive summary
Part 02: Scope of the report
Part 03: Market research methodology
Part 04: Introduction
Part 05: Pharmaceutical manufacturing outsourcing
Part 06: Market landscape
Part 07: Market segmentation by type of contract manufacturing
Part 08: Geographical segmentation
Part 09: Key leading countries
Part 10: Market drivers
Part 11: Impact of drivers
Part 12: Market challenges
Part 13: Impact of drivers and challenges
Part 14: Market trends
Part 15: Vendor landscape
Part 16: Key vendor analysis
Part 17: Appendix
For more information about this report visit http://www.researchandmarkets.com/research/mhzdln/global
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Pharmaceuticals, Pharmaceutical Manufacturing


Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Apple Turns 50: From Garage Startup to AI Crossroads
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
Bank of America's $72.5M Epstein Settlement: What You Need to Know
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 



